Erika MacIntyre

Erika MacIntyre

Auto-generated profile, based on publicly available information

Erika MacIntyre

University of Alberta, Edmonton, AB, Canada

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Hypertension
Verified
Journal Article
Closed access
PDF file
KWKaiming Wang
Kaiming Wang
MGMahmoud Gheblawi
Mahmoud Gheblawi
ANAnish Nikhanj
Anish Nikhanj
MMMatt Munan
Matt Munan
EMErika MacIntyre
Erika MacIntyre
GOGavin Oudit
Gavin Oudit
ACE (angiotensin-converting enzyme)-2 as the target for SARS-CoV-2 also negatively regulates the renin-angiotensin system. Pathological activation of ADAM17 (A disintegrin and metalloproteinase-17) may potentiate inflammation and diminish ACE2-mediated tissue protection through proteolytic shedding, contributing to SARS-CoV-2 pathogenesis. We aim to examine plasma soluble ACE2 and angiotensin profiles in relation to outcomes by enrolling consecutive patients admitted for COVID-19 with baseline blood collection at admission and repeated sampling at 7 days. The primary outcome was 90-day mortality, and secondary outcomes were the incidence of end-organ injuries. Overall, 242 patients were included, the median age was 63 (52–74) years, 155 (64.0%) were men, and 57 (23.6%) patients reached the primary end point. Baseline soluble ACE2 was elevated in COVID-19 but was not associated with disease severity or mortality. In contrast, an upward trajectory of soluble ACE2 at repeat sampling was independently associated with an elevated risk of mortality and incidence of acute myocardial injury and circulatory shock. Similarly, an increase in soluble tumor necrosis factor receptor levels was also associated with adverse outcomes. Plasma Ang I, Ang 1-7 (angiotensin 1–7) levels, and the Ang 1-7/Ang II (angiotensin II) ratio were elevated during SARS-CoV-2 infection related to downregulation of ACE activity at baseline. Moreover, patients having an upward trajectory of soluble ACE2 were characterized by an imbalance in the Ang 1-7/Ang II ratio. The observed dysregulation of ACE2 and angiotensin peptides with disease progression suggest a potential role of ADAM17 inhibition and enhancing the beneficial Ang 1-7/Mas axis to improve outcomes against SARS-CoV-2 infection.

26 October 2020 in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
Verified
Journal Article
Closed access
PDF file
MMMatthew Munan
Matthew Munan
WLWesterly Luth
Westerly Luth
SGShelagh K. Genuis
Shelagh K. Genuis
WJWendy S.W. Johnston
Wendy S.W. Johnston
EMErika MacIntyre
Erika MacIntyre
Background: Amyotrophic lateral sclerosis (ALS) presents many transitions for persons/people with ALS (PwALS) and their caregivers. Transitions are passages from one life phase, condition, or status to another. We used qualitative methods to understand how PwALS and caregivers experience transitions throughout their ALS journey.Methods: PwALS and their caregivers were recruited from a multidisciplinary ALS clinic in Edmonton, Canada. We recruited patients at the stage of ALS that home mechanical ventilation, a feeding tube, and/or assistive communication technology had been offered. Semi-structured interviews were audio-recorded, transcribed, and analyzed using qualitative thematic analysis.Results: We interviewed 14 PwALS and 15 caregivers and identified 5 recurring themes. The importance of community was identified by many PwALS and caregivers who expressed feelings of loneliness and isolation. Most caregivers were spouses and couples navigated a change in their relationship roles as one spouse transitioned to becoming a caregiver while the other transitioned to dependency. The caregiver spouses reported a sense of “total responsibility” that encompassed continual vigilance for the PwALS’s well-being, managing their household and finances. PwALS and caregivers reported transitioning to reliance on life-sustaining medical devices; early adoption and information on these devices increased their quality of life. Participants also wanted more and earlier information on advanced care planning. PwALS and caregivers identified adapting to new forms of communication as a necessity.Conclusion: ALS presents many transitions for PwALS and caregivers. Understanding these transitions is important for ALS healthcare professionals who seek to implement best care practices.

4 December 2024 in Critical Care Medicine
Verified
Journal Article
Open access
SKSebastian J. Bsc Kilcommons
Sebastian J. Bsc Kilcommons
FHFadi Hammal
Fadi Hammal
MKMostafa Kamaleldin
Mostafa Kamaleldin
DODawn L. Opgenorth
Dawn L. Opgenorth
KFKirsten M. Fiest
Kirsten M. Fiest
OROleksa G. Md Rewa
Oleksa G. Md Rewa
OBJECTIVES: To summarize the efficacy of midodrine as an adjunctive therapy in critically ill patients. Safety of midodrine was assessed as a secondary outcome. DATA SOURCES: We performed a systematic review and meta-analysis using a peer-reviewed search strategy combining the themes of vasopressor-dependent shock, critical care, and midodrine and including MEDLINE, Ovid Embase, CINAHL, and Cochrane library databases until September 14, 2023. STUDY SELECTION: We included studies if they: 1) included patients with vasopressor-dependent shock, 2) were performed in the ICU, 3) evaluated oral midodrine therapy compared with placebo or usual care, and 4) evaluated one of the outcomes of interest. DATA EXTRACTION: We extracted data independently in duplicate using standardized data abstraction forms, which included the following specific variables: patient characteristics, age, sex, type of ICU, etiology of shock, number of patients, study inclusion and exclusion criteria, and geographical location. We also captured the type, dose, and duration of IV vasopressors, any cointervention used, and outcome data. DATA SYNTHESIS: We identified seven randomized controlled trials (six included in the pooled analysis) and ten observational studies (four included in the pooled analysis) that met eligibility criteria. Adjunctive midodrine may decrease ICU length of stay (LOS) and there is low certainty of effect on hospital LOS. Midodrine may decrease IV vasopressor support duration, ICU mortality, and hospital mortality. Pooled observational data was based on very low certainty data for all outcomes of interest. The trial sequential analysis-informed required sample size was not met for ICU LOS or IV vasopressor duration and this contributed to Grading of Recommendations, Assessment, Development, and Evaluations assessments of imprecision for both outcomes. CONCLUSIONS: Adjunctive midodrine may decrease ICU LOS, duration of IV vasopressor therapy, and mortality in critically ill patients. However, required sample sizes was not met to determine our outcomes of interest. Midodrine may increase risk of bradycardia. While midodrine may provide benefit for patient-centered outcomes, due to increased risk of adverse events, further large-scale studies are needed to inform and guide its routine use in the ICU.

4 March 2022 in Trials
Verified
Journal Article
Open access
PDF file
DODawn Opgenorth
Dawn Opgenorth
NBNadia Baig
Nadia Baig
KFKirsten M. Fiest
Kirsten M. Fiest
CKConstantine Karvellas
Constantine Karvellas
JKJim Kutsogiannis
Jim Kutsogiannis
OROleksa G. Rewa
Oleksa G. Rewa
Background: Intravenous (IV) vasopressors to support hemodynamics are a primary indication for intensive care unit (ICU) admission. Utilization of oral vasopressor therapy may offer an alternative to IV vasopressor therapy in the ICU, thus decreasing the need for ICU admission. Oral vasopressors, such as midodrine, have been used for hemodynamic support in non-critically ill patients, but their evaluation in critically ill patients to potentially spare IV vasopressor therapy has been limited. Methods: The LIBERATE study will be a multicenter, parallel-group, blinded, randomized placebo-controlled trial. It will recruit adult (i.e., age ≥ 18 years) critically ill patients receiving stable or decreasing doses of IV vasopressors. Eligible patients will be randomized to receive either midodrine 10 mg administered enterally every 8 h or placebo until 24 h post-discontinuation of IV vasopressors. The primary outcome will be ICU length of stay. Secondary outcomes include all-cause mortality at 90 days, hospital length of stay, length of IV vasopressor support, re-initiation of IV vasopressors, rates of ICU readmission, and occurrence of AEs. Health economic outcomes including ICU, hospital and healthcare costs, and cost-effectiveness will be evaluated. Pre-planned subgroup analyses include age, sex, frailty, severity of illness, etiology of shock, and comorbid conditions. Discussion: LIBERATE will rigorously evaluate the effect of oral midodrine on duration of ICU stay and IV vasopressor support in critically ill patients. Trial registration: ClinicalTrials.gov NCT05058612. Registered on September 28, 2021

2 April 2020 in Canadian Journal of Respiratory, Critical Care, and Sleep Medicine
Verified
Journal Article
Closed access
EMErika MacIntyre
Erika MacIntyre
JBJeffrey A. Bakal
Jeffrey A. Bakal
SBSean Bagshaw
Sean Bagshaw
JMJoanna E. MacLean
Joanna E. MacLean
RATIONALE: The prevalence of children supported with home mechanical ventilation (HMV) is growing and advances in medical care have led to an increasing number surviving to adulthood. Transition to adult healthcare services is poorly described.

7 February 2023 in Canadian Journal of Respiratory, Critical Care, and Sleep Medicine
Verified
Journal Article
Closed access
MMMatt Munan
Matt Munan
ZHZoe Hsu
Zoe Hsu
JBJeffrey A. Bakal
Jeffrey A. Bakal
EMErika MacIntyre
Erika MacIntyre
Patients requiring Prolonged Mechanical Ventilation (PMV) are a small but important subset of critically ill patients treated in an Intensive Care Unit (ICU). The purpose of this study is to identify and characterize the PMV population in Alberta, Canada over a period of 10 years and to determine mortality, discharge disposition and healthcare cost. A search of the Alberta Health Services Enterprise Data Warehouse was performed to characterize all patients with 7 days or more of mechanical ventilation in an acute care hospital in Alberta from 2009-2019. Data linkages were performed to identify survival up to 2 years and Healthcare cost was estimated using resource intensity weight (RIW) score. The search identified 11,739 patients ventilated for ≥7 days from 2009-2019. In this cohort, 59% of patients were ventilated for 7-13 days, 20% for 14-20 days and 21% for 21 days or more. The in-hospital survival rate was 68% and the one-year survival from initiation of ventilation was 61%. Of the patients discharged alive, 93% were discharged to community and 7% were discharged to a continuing care center. The median healthcare cost for index hospital admission was $119,627 ($70,549-$200,036) PMV users require a significant duration of mechanical ventilation, a prolonged stay in the ICU and hospital and high healthcare resource utilization. The majority of these patients survive their index admission and are discharged to community.